Lupin launches generic solution for conjuctivitis in US


Mumbai, Oct 3 (IANS): Drug maker Lupin Thursday said it has launched the generic version of Allergan Inc's Zymaxid Ophthalmic Solution in the US market with 180 days of marketing exclusivity.

Lupin Pharmaceuticals Inc, the company's US subsidiary, launched its generic Gatifloxacin Ophthalmic Solution 0.5 percent in the US market, after having received the regulator's final approval earlier, Lupin said in a statement.

Gatifloxacin Ophthalmic Solution 0.5 percent, which is the generic equivalent of Zymaxid Ophthalmic Solution of Allergan, is indicated for the treatment of bacterial conjunctivitis.

"Zymaxid Ophthalmic Solution 0.5 percent had annual US sales of around $62.3 million, acording to IMS MAT data. Lupin was the first applicant to file an abbreviated new drug application (ANDA) for Zymaxid Ophthalmic Solution and as such will be entitled to 180 days of marketing exclusivity," the company said.

Lupin has been focusing on less competitive specialities spaces in the US market which includes segments like Oral Contraceptives, Ophthalmology and Dermatology.

 

  

Top Stories


Leave a Comment

Title: Lupin launches generic solution for conjuctivitis in US



You have 2000 characters left.

Disclaimer:

Please write your correct name and email address. Kindly do not post any personal, abusive, defamatory, infringing, obscene, indecent, discriminatory or unlawful or similar comments. Daijiworld.com will not be responsible for any defamatory message posted under this article.

Please note that sending false messages to insult, defame, intimidate, mislead or deceive people or to intentionally cause public disorder is punishable under law. It is obligatory on Daijiworld to provide the IP address and other details of senders of such comments, to the authority concerned upon request.

Hence, sending offensive comments using daijiworld will be purely at your own risk, and in no way will Daijiworld.com be held responsible.